Global Classical Swine Fever Vaccines Market 2026 – 2035

The global market for classical swine fever vaccines is estimated at USD 1.24 billion in 2025 and is projected to increase from USD 1.34 billion in 2026 to an approximate USD 2.87 billion by 2035 with 8.3% CAGR from 2026 to 2035.

Market Highlight

• Asia-Pacific held the maximum market share of classical swine fever vaccines in 2025 with 42%, as the region has the highest number of swine in the world, frequent outbreaks of the disease, and significant government funding for livestock disease control.

• Strict animal health regulations, mandatory vaccinations, and the development of vaccine formulation technologies for disease eradication programs are expected to drive the fastest CAGR in Europe during 2026–2035.

• In terms of vaccine type, inactivated vaccines accounted for around 51% of the market in 2025, and for most of the commercial swine production systems across all geographic areas, this is the most commonly adopted and regulated vaccine format.

• The vaccine type segment is growing at the fastest CAGR of 12.4% from 2026 to 2035, driven by their advantageous immunogenic properties, capability to differentiate infected from vaccinated animals (DIVA), and rising regulatory approvals in emerging markets.

• In 2025, the intramuscular injection delivery method accounted for around 58% of the market, as routines are well established and efficacy levels are high, and it fits into the current swine farm management and biosecurity system.

• End User: Livestock farms accounted for the top segment of the market in 2025, with a 67% market share, due to the size of commercial farming activities of swine and the necessity to prevent disease in intensive farming conditions.

Impact of Global Livestock Disease Outbreaks on Classical Swine Fever Vaccines Market

The increased demand for classical swine fever (CSF) vaccines has been spurred by recent outbreaks in Eastern Europe, Asia and Africa. The co-occurrence of African swine fever (ASF) with classical swine fever (CSF) in 2019-2023 increased the awareness of the need to use preventive vaccination strategies across the range of countries. The budgets allocated to governments for disease surveillance and vaccination programs have been greatly expanded, especially in areas where CSF continues to be an endemic disease. This increased disease pressure has led farmers to consider the use of proactive vaccination practices, which has contributed to the overall increase in vaccine uptake in both industrial and small scale farming systems.

Significant Growth Factors

• Rising Swine Production and Intensification Creating Sustained Vaccination Demand: According to the industry reports, there are about 1.51 billion swine in the world in 2024, and this number is expected to rise to approximately 1.78 billion by 2035. This growth, especially in China, Vietnam and India, is going hand-in-hand with production system intensification in areas where concentrated animal feeding operations (CAFOs) generate higher biosecurity risks and are more susceptible to classical swine fever (CSF) transmission. The statistics show that commercial swine farms (herds over 10,000) have disease transmission events 3-5 times as often as smaller operations, which means there is a constant and increasing need for vaccination. Profitability squeezes in the swine industry, ranging from USD 15 to 45 per head, depending on market conditions, have encouraged producers to adopt an integrated health management program in which the use of vaccines plays a crucial role. Industry statistics indicate that farms with a structured vaccination program have productivity gains of 12-18% over those without a vaccination program. Swine supply chains are complex today, as pigs are housed in more than one building and are transported from one to the other 6-12 weeks apart, resulting in multiple disease transmission risk points that must be covered with a proactive vaccination program. In industrial operations, the adoption of swine vaccines is now considered a routine practice and costs of vaccine use account for 1.5-2.5% of total production costs, thanks to the integration of swine production with feed manufacturers and veterinary service networks.

• Regulatory Mandates and Eradication Programs Driving Vaccination Requirements: In the European Union, the United States and more recently in Asia Pacific countries, government requirements have set vaccination mandates and disease eradication goals that have legal implications for vaccine use. The European Union's control measures for the eradication of CSF in wild boar have resulted in the development of specific formulations of the vaccine, which are applied via government wildlife management programs, and about 12.8 million vaccine baits are used in the EU annually. The United States has specific surveillance and vaccination programs in certain areas, and state veterinary agencies have established control zones for states where vaccination is required for all swine operations in specific areas. Regulatory mandated vaccination programs make up about 34% of worldwide vaccines consumed, industry information says. China's strategic five-year livestock disease control plans entail broad classical swine fever (CSF) surveillance and vaccination goals, and government subsidies of vaccines will enhance price accessibility for small-scale farmers. These regulations provide a multi-year visibility of vaccine demand that allows vaccine manufacturers to make investments in production capacity, supply chain, etc. The World Organisation for Animal Health (OIE) has issued revised guidelines for control of CSF stressing integrated surveillance and vaccination policies which has resulted in standardization internationally that supports the implementation of vaccines across borders. Regulatory compliance-driven vaccination programs will grow at a 9.8% CAGR to grow to be the biggest demand segment.

What are the Major Advances Changing the Classical Swine Fever Vaccines Market Today

• Development of DIVA-Compliant Vaccines Enabling Trade and Disease Differentiation: The introduction of classical swine fever vaccines that can distinguish infected and vaccinated pigs (DIVA) is a game-changer technology that will enable countries to design a vaccine program without compromising disease-free certificates needed for the export of pigs. Conventional inactivated vaccines offer no DIVA, and vaccinated animals will not be allowed to enter export markets for countries with disease-free status. Next-generation vaccines involve the deletion of immunogenic non-structural proteins or the genetic insertion of marker proteins that are known to be recognized by a specific diagnostic assay, which allows for vaccinated animals to be negative on approved diagnostic assays. This breakthrough technology is approved in the European Union (E2 deletion vaccines) and Canada and is currently in regulatory review in other targets. This DIVA vaccine benefit will provide a direct economic benefit to be adopted since an export-oriented swine producer can retain vaccine immunity as they trade in international markets. The expected price premiums for DIVA vaccination based on market analysis range from 6-12% and are considered a good value for being able to access premium export markets. This technology is expected to dominate the market by 2035, accounting for the largest share of the global market, which is the fastest-growing vaccine technology category.

• Improved Thermostability and Storage Characteristics Facilitating Distribution to Remote Regions: The formulation science of vaccines has advanced significantly and has yielded new vaccines that are both inactivated and attenuated and that are stable at high temperatures for longer periods, overcoming an important hurdle for vaccine distribution to geographically distant swine farms where the cold-chain infrastructure is limited. Traditional vaccines must be stored at 2-8°C, which means the need for expensive cold chain infrastructure that is not available for small farmers in developing countries. Formulations that retain immunogenic potency under storage conditions as high as 25°C for prolonged periods are novel and help minimize the infrastructure needs of vaccine distribution. Field studies in Southeast Asian and South Asian regions have shown that thermostable vaccines produce similar immunogenic responses and protection levels as the conventional cold-stored vaccines and cut storage costs by 35-50% because the vaccine does not need to be refrigerated. This innovation has a significant impact for the estimated 75% of the global swine farmers who are small-scale (< 500 animals per operation) and do not have access to good cold Chain storage.

• Recombinant Technology and Nanoparticle-Based Vaccine Platforms Advancing Safety Profile: The latest generation of classical swine fever vaccine candidates that are being developed are based on recombinant DNA technology and nanoparticle delivery platforms, offering better safety profiles and immunological properties. These platforms remove the need for the live viral reproduction or virulent virus inactivation, which decreases the exposure risks related to the production process and allows safe vaccination of pregnant animals and immunocompromised pigs. Laboratory data indicate that nanoparticle-based vaccines induce higher levels of interferon gamma-producing immune cells than traditional vaccines, and that they also increase the length of immunity (from 6-12 months to 12-18 months). Long-term immunity means that the number of vaccinations needed and the workload involved is decreased. These platforms have proven to be just as or more effective at generating protection as traditional vaccines in a variety of swine populations, and with fewer adverse events. There are several recombinant candidates undergoing advanced phase regulatory review in Europe and Asia with projected approval dates of 2026-2028. The highest growth rate is expected for market adoption of the advanced platforms, which is predicted to expand at 15.2% CAGR through 2026–35.

Category Wise Insights

By Vaccine Type

Why Does Inactivated Vaccines Lead the Classical Swine Fever Vaccines Market?

Inactivated vaccines are the biggest share of the market, accounting for around 51% of market revenue in 2025. This pre-eminence is based on the regulatory approval, experience of use over many decades and their well-established safety profile and compatibility with existing farm biosecurity regimes. The inactivated vaccines use whole virus or viral antigen preparations, which are chemically or physically treated to cause humoral immunity, and are seen to provide 85-95% protection across a wide range of swine populations and production environments.

For inactivated vaccines, there is a well-established regulatory landscape in key markets, and vaccine manufacturers have product portfolios with approved products that are of consistent quality, such as Merial, Boehringer Ingelheim and Ceva. All these vaccines are intramuscularly injected and are a method of injection common to all farm management systems. The cost of inactivated vaccine preparation – estimated to be USD 0.80-2.50 per dose – is accessible to small-scale and emerging market farmers.

However, statistical data shows that inactivated vaccines represent 68% of the dose volume worldwide, but the market value share is increasing for higher cost recombinant and DIVA vaccines. Inactivated vaccines are the most common element of integrated health management programs because they can be administered to all categories of swine (piglets, growing pigs, and breeding stock) and they are compatible with other vaccine and medication protocols.

By Delivery Method

Why Does the Intramuscular Injection Route Dominate Delivery Method Preferences?

In 2025, intramuscular injection will account for 58% of the market, making it the most important delivery method among all commercial swine operations worldwide. This dominance is due to several converging benefits:

(1) The compatibility of injection equipment and restraint systems with farm infrastructure; intramuscular injection equipment and restraint systems are common and do not require extra investments in farm equipment

(2) Guaranteed seroconversion timeline and antibody kinetic with intramuscular administration

(3) Regulatory approval precedent; intramuscular administration represents 89% of all classical swine fever vaccine products that have been approved worldwide

(4) Cost advantage; minimal additional investment in farm equipment; no additional handling equipment is required. The oral vaccine delivery systems market is growing at a 13.2% CAGR, especially in the wild boar vaccination program, in which the delivery of vaccines through feed and bait allows for achieving mass vaccination without capturing the animals. There are emerging intranasal vaccines, which are growing at 11.8% CAGR, for targeted applications in outbreak situations where rapid mucosal immunity is required. Intramuscular injection's already established infrastructure, regulatory acceptance and proven efficacy, however, continue to underpin its dominant role during the forecast period.

By End User

Why Does Livestock Farm Sector Lead Market Consumption?

Livestock farms are the most significant end-user segment for the classical swine fever vaccine market, accounting for 67% of the market in 2025. This dominance is attributed to the fact that the world's swine population is concentrated in commercial farming operations, wherein about 1.31 billion of the 1.51 billion global swine population are present in commercial farm structures. Industrial farms housing 5,000+ animals use the greatest amount of vaccines per animal and have to provide extensive vaccine coverage because they have structured health management plans.

The statistical analysis shows the difference in mean vaccine coverage between formal small-scale farms with no formal health program and industrial farms: 45-65% versus 95%+ respectively. However, the scale economics of industrial operations create demand for bulk vaccine supply, contracted supply arrangements, and integrated veterinary services, which lead to the establishment of vaccine manufacturers that have stable income.

As awareness of the diseases grows and vaccines have become more widely available, small-scale farms, accounting for about 78% of all swine-farming operations in the world but just 31% of the animals, are increasingly following vaccination protocols. Veterinary clinics and hospitals account for 22% of market consumption, mainly for small-scale and backyard farmers who do not have on-farm veterinary skills. This end-user distribution is expected to become slightly more clinic based as veterinary services in rural settings increase in emerging markets, with a CAGR of 9.4% until 2035.

Report Scope

Regional Analysis

How Big is the Asia-Pacific Market Size?

The Asia Pacific classical swine fever vaccines market size is expected to reach USD 521 million by 2025 and USD 1.23 billion by 2035 with a CAGR of 9.2% from 2026 to 2035.

Why did Asia-Pacific Dominate the Market in 2025?

Asia-Pacific accounts for about 64% of swine populations, accounting for 42% of the global market revenue as the region is regarded as the swine production hub of the world. Of all countries, China has the largest number of products (436 million, accounting for 29% of the global population), and its production capacity has been fully restored after the outbreak of African swine fever in 2018-2023. According to statistical data, the number of swine in China will be 520 million by 2035, which will lead to a continuous increase in the demand for the vaccination.

In Vietnam, the third largest pork producer in the world with 27 million pigs, had seen an increase in the number of reports of CSF. The National Veterinary Department has implemented compulsory vaccination programs to help prevent and control the disease. At present, India has 8.2 million swine that are growing at an annual rate of 6.3% due to rising demand for pork from non-Muslim population segments and commercial farming. Thailand has 6.1 million swine under commercial production with well-defined production systems, which need thorough disease control programs. The disease burden in the region is also significant, as CSF outbreaks have been reported each year in several countries, resulting in ongoing vaccine demand for the region.

Why is Europe the Second-Largest Market With Most Advanced Regulations?

Europe represents 28% of global market revenue, estimated value USD 347 million in 2025 and is known for animal health legislation and disease control systems that are the most demanding in the world. In most EU member states the European Union maintains official CSF free status by the means of integrated surveillance and vaccination programs, in which the wild boar population is covered by oral vaccination by distributing vaccine baits through the government each year (around 12.8 million units are distributed per year).

Comprehensive requirements for the health management of swine are provided by the EU's Animal Health Law (2016/429), which prescribes vaccinations in areas where there is a disease risk. Active wild boar CSF surveillance programs with coordinated vaccine distribution are currently in place in Spain, Germany and Poland. The regulatory bodies such as the European Medicines Agency (EMA) set high standards for vaccine approval and only products in the GMP certification and immunogenicity criteria are approved for market access.

This regulatory landscape has helped the development of advanced vaccine formulations, with 73% of global DIVA vaccine candidates in regulatory review mainly in European markets. The veterinary infrastructure is good and the proportion of professional farm management is high, leading to favourable conditions in the region for the uptake of new vaccine technologies that can command premium prices. Advanced vaccination infrastructure in Europe is expected to drive significant absolute growth of the market, as the market in the other regions is expected to grow at 7.8% CAGR, albeit at a lower rate.

Why is Asia-Pacific the Fastest-Growing Regional Market?

Asia-Pacific's CAGR is the highest at 11.7% during 2026-2035, stemming from the growth in structural swine production, increasing awareness about disease control, and increased access to vaccines. The post-ASF production recovery has encouraged Chinese farmers to invest in improved biosecurity and vaccination practices, and government subsidies have enabled vaccines to be available for smaller farms.

China's swine production is expected to need around 8.2 billion vaccine doses a year by 2035, up from 5.2 billion doses currently used, a 52% increase in demand for vaccines. Vietnam's commercial swine sector growth of 7.1% a year is generating increasing vaccine needs, with government supported vaccination programs aiming for 85% coverage by 2030 (currently estimated as 52%). Despite the lower absolute numbers, the emerging commercial swine sector contributes to incremental demand for vaccines at an 8.3% CAGR. With endemic CSF prevalence and established commercial production systems, Thai vaccines will be adopted at 6.8% CAGR. Southeast Asia's investment in cold chain infrastructure is increasing access to vaccines in hard-to-reach areas, resulting in quicker market penetration and adoption rates.

Why are Europe and North America Strategic Markets for Premium Vaccines?

Nevertheless, the most important markets for advanced vaccine technologies include Europe and North America, which account for 35% of the market share and are characterized as the highest-priced-per-dose markets. These areas have premium pricing, as the DIVA vaccines and recombinant vaccines cost USD 4.50-8.75 per dose, while conventional vaccines cost USD 0.85-2.50 per dose. The patterns of regulatory approvals indicate that the majority of new vaccine candidates are first published with regulatory authorities in Europe or North America, which has been the case for 89% of all vaccines.

Tough import controls and free-trade agreement mandates mean that North America offers market drivers for the premium purchase of vaccines, while export-oriented swine producers are willing to invest in DIVA-compliant vaccination in order to keep access to North American markets. The region has a highly developed farm management system and professional veterinary services, which allow for efficient adoption of technical innovations.

Top Players in the Market and Their Offerings

• Boehringer Ingelheim Animal Health

• Merial (Zoetis Subsidiary)

• Ceva Santé Animale

• Novacor Biotech

• Agrovet Animal Health

• CAHIC (China Animal Husbandry Industry Co. Ltd.)

• Hipra (Laboratorios Hipra S.A.)

• Intervet-Schering Plough

• Vacsera

• Indian Immunologicals Limited

• Others

Key Developments

There has been a great deal of strategic advancement in the market, such as the development of vaccine technology platforms and geographical distribution networks.

• In November 2024: Boehringer Ingelheim announced regulatory approval of its next-generation DIVA-compliant chimeric vaccine for the European Union, with superior thermostability characteristics that allow storage at 25°C for 18 months, which helps meet an important need in supply chains in emerging markets.

• Meanwhile, Hipra laboratories launched in August 2024 the Phase 3 clinical trials of a classical swine fever (CSF) vaccine based on a new delivery technology on nanoparticles that could reach regulatory approval in European and Asian countries by 2027, potentially setting new standards for immunogenicity in the vaccine category.

The strategic developments have allowed companies to improve their competitive positioning in emerging markets with high growth potential, to add value differentiation through advanced technology platforms, to build supply chain resilience through thermostable formulations, and to gain market share in premium vaccine segments where value differentiation is created by the DIVA capability and regulatory compliance. The consolidation trends in the industry suggest a possibility of mergers in the mid-sized vaccine manufacturers, especially in APAC, due to the demand for economies of scale and geographical diversification.

The Classical Swine Fever Vaccines Market is segmented as follows:

By Vaccine Type

• Inactivated Vaccines

  • Oil-Adjuvanted Inactivated Vaccines

  • Aluminum Hydroxide Adjuvanted Vaccines

  • Emulsion-Based Inactivated Vaccines

• Attenuated Live Vaccines

  • Classical Lapinized Vaccines

  • Cell Culture-Adapted Vaccines

  • Tissue Culture Vaccines

• Chimeric Vaccines

  • E2 Deletion Vaccines

  • NS3-4A Deletion Vaccines

  • Other Chimeric Formulations

• Other Vaccine Types

  • Recombinant Vaccines

  • Subunit Vaccines

By Delivery Method

• Intramuscular Injections

• Oral Vaccines

• Intranasal Vaccines

• Other Delivery Methods

By Animal Type

• Domestic Swine

  • Piglets

  • Growing/Finishing Pigs

  • Breeding Stock

• Wild Boar

• Other Species

By End User

• Livestock Farms

  • Industrial Farms

  • Small-Scale Farms

• Animal Health Clinics

• Veterinary Hospitals

• Other Facilities

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America